105 related articles for article (PubMed ID: 7273488)
1. The effects of three different heparin regimes on heparin concentrations in plasma and fibrin formation in dialyzers.
Gunnarsson B; Asaba H; Dawidson S; Wilhelmsson S; Bergström J
Clin Nephrol; 1981 Mar; 15(3):135-42. PubMed ID: 7273488
[TBL] [Abstract][Full Text] [Related]
2. Measurement of fibrinopeptide A in the evaluation of heparin activity and fibrin formation during hemodialysis.
Wilhelmsson S; Asaba H; Gunnarsson B; Kudryk B; Robinson D; Bergström J
Clin Nephrol; 1981 May; 15(5):252-8. PubMed ID: 7249422
[TBL] [Abstract][Full Text] [Related]
3. Objective assessment of heparin requirements for hemodialysis in humans.
Ireland H; Lane DA; Curtis JR
J Lab Clin Med; 1984 Apr; 103(4):643-52. PubMed ID: 6230409
[TBL] [Abstract][Full Text] [Related]
4. A low molecular weight heparin ("fragmin") for routine hemodialysis: a crossover trial comparing three dose regimens with a standard regimen of commercial unfractionated heparin.
Anastassiades E; Lane DA; Ireland H; Flynn A; Curtis JR
Clin Nephrol; 1989 Dec; 32(6):290-6. PubMed ID: 2558829
[TBL] [Abstract][Full Text] [Related]
5. A single dose of a low molecular weight heparin fragment for anticoagulation during hemodialysis.
Ljungberg B; Blombäck M; Johnsson H; Lins LE
Clin Nephrol; 1987 Jan; 27(1):31-5. PubMed ID: 3815906
[TBL] [Abstract][Full Text] [Related]
6. Haemodialysis with low MW heparin: dosage requirements for the elimination of extracorporeal fibrin formation.
Lane DA; Ireland H; Flynn A; Anastassiades E; Curtis JR
Nephrol Dial Transplant; 1986; 1(3):179-87. PubMed ID: 2955253
[TBL] [Abstract][Full Text] [Related]
7. Intraperitoneal fibrin-formation and its inhibition in CAPD.
Gries E; Paar D; Graben N; Bock KD
Clin Nephrol; 1986 Oct; 26(4):209-12. PubMed ID: 3780071
[TBL] [Abstract][Full Text] [Related]
8. The influence of dialyzer geometry on blood coagulation and biocompatibility.
Lins LE; Boberg U; Jacobson SH; Kjellstrand C; Ljungberg B; Skröder R
Clin Nephrol; 1993 Nov; 40(5):281-5. PubMed ID: 8281717
[TBL] [Abstract][Full Text] [Related]
9. Fibrin formation and platelet aggregation in patients with acute myocardial infarction: effects of intravenous and subcutaneous low-dose heparin.
Gallino A; Haeberli A; Hess T; Mombelli G; Straub PW
Am Heart J; 1986 Aug; 112(2):285-90. PubMed ID: 2426934
[TBL] [Abstract][Full Text] [Related]
10. Whole-blood activated coagulation time for evaluation of heparin activity during hemodialysis: a comparison of administration by single-dose and by infusion.
Wilhelmsson S; Lins LE
Clin Nephrol; 1983 Feb; 19(2):82-6. PubMed ID: 6839556
[TBL] [Abstract][Full Text] [Related]
11. A low molecular heparin fraction as an anticoagulant during hemodialysis.
Ljungberg B
Clin Nephrol; 1985 Jul; 24(1):15-20. PubMed ID: 4017295
[TBL] [Abstract][Full Text] [Related]
12. Fibrin deposition in disposable dialyzers before and after re-use.
Gunnarsson B; Asaba H; Kiibus A; Söderborg B; Wiklund S; Bergström J
Clin Nephrol; 1979 Sep; 12(3):117-21. PubMed ID: 509786
[TBL] [Abstract][Full Text] [Related]
13. Heparin elimination and hemostasis in hemodialysis.
Wilhelmsson S; Lins LE
Clin Nephrol; 1984 Dec; 22(6):303-6. PubMed ID: 6525772
[TBL] [Abstract][Full Text] [Related]
14. Increased binding of beta-2-microglobulin to blood cells in dialysis patients treated with high-flux dialyzers compared with low-flux membranes contributed to reduced beta-2-microglobulin concentrations. Results of a cross-over study.
Traut M; Haufe CC; Eismann U; Deppisch RM; Stein G; Wolf G
Blood Purif; 2007; 25(5-6):432-40. PubMed ID: 17957097
[TBL] [Abstract][Full Text] [Related]
15. Conjunctive administration of intravenous heparin attenuates cross-linked fibrin degradation in patients treated with streptokinase.
Galvani M; Abendschein DR; Ferrini D; Ottani F; Rusticali F; Eisenberg PR
Thromb Haemost; 1996 Sep; 76(3):339-43. PubMed ID: 8883267
[TBL] [Abstract][Full Text] [Related]
16. Prothrombin fragment 1 + 2, thrombin-antithrombin III-complexes and fibrinopeptide A in spontaneously clotting whole blood in vitro. Effects of heparin addition and antithrombin III deficiency.
Herren T; Straub PW; Haeberli A
Thromb Haemost; 1994 Jan; 71(1):49-53. PubMed ID: 8165646
[TBL] [Abstract][Full Text] [Related]
17. Effect of a sliding scale protocol for heparin on the ability to maintain whole blood activated partial thromboplastin times within a desired range in hemodialysis patients.
Low CL; Bailie G; Morgan S; Eisele G
Clin Nephrol; 1996 Feb; 45(2):120-4. PubMed ID: 8846524
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamics of unfractionated heparin during and after a hemodialysis session.
Brunet P; Simon N; Opris A; Faure V; Lorec-Penet AM; Portugal H; Dussol B; Berland Y
Am J Kidney Dis; 2008 May; 51(5):789-95. PubMed ID: 18436089
[TBL] [Abstract][Full Text] [Related]
19. On the evaluation of heparin and low molecular weight heparin in haemodialysis for chronic renal failure.
Lane DA; Flynn A; Ireland H; Anastassiades E; Curtis JR
Haemostasis; 1986; 16 Suppl 2():38-47. PubMed ID: 3744134
[TBL] [Abstract][Full Text] [Related]
20. Effect of heparin on plasma fibrinopeptide A in patients with acute myocardial infarction.
Mombelli G; Im Hof V; Haeberli A; Straub PW
Circulation; 1984 Apr; 69(4):684-9. PubMed ID: 6697455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
